ArticleAnnals of hematology2026
Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Evans syndrome, characterized by autoimmune hemolytic anemia and immune thrombocytopenia, is rare and often refractory to conventional therapies. In Chinese patients with systemic lupus erythematosus (SLE), its incidence is approximately 0.47%. We report the first case of anti-CD19 chimeric antigen receptor (CAR) T cell therapy for SLE-Evans syndrome. A 36-year-old woman with refractory disease received autologous CD19 CAR T cells (inati-cel) after lymphodepleting chemotherapy. CAR T cells expanded rapidly, peaking on day 7, and remained detectable for 6 months. CD19 B cells were eliminated by day 14. Hemoglobin levels improved from 48 g/L pre-infusion to 115 g/L at day 28 and stabilized. Platelet counts increased from 60,000/µL to 195,000/µL at 2 months. Only grade 1 cytokine release syndrome occurred, with no other adverse events. This case demonstrates that CD19 CAR T cell therapy is a promising approach for refractory Evans syndrome, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.